검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Sotorasib |
Overview Company | Amgen |
Overview Modality | ADC |
Overview Target | Locally Advanced Lung Non-Small Cell Car |
Overview Indication | Colorectal Cancer; Resectable Colorectal Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | binds to G12C mutant KRAS with high affinity and suppresses nucleotide exchange and MAPK signaling |
MoA Biomarker | biomarker-guided treatment algorithms will be essential |
PK/PD Half-life | 5.2 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Sotorasib induces intestinal epithelial injury through suppression of the cAMP/PKA/CREB signaling axis.. Sotorasib, a first-in-class KRAS G12C inhibitor, has demonstrated substantial clinical efficacy in KRAS G12C-mutant malignancies but is frequently associated with gastrointestinal adverse events, the mechanisms of which remain poorly understood. In this study, we investigated the molecular basi… |
Clinical ORR | 0% |
Clinical PFS | 0 |
Clinical OS | 0.75 |
Clinical Result source | ClinicalTrials.gov NCT05313009 |
Clinical Data Tier / Score | A · 42 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Sotorasib |
Overview Company | Amgen |
Overview Modality | ADC |
Overview Target | Locally Advanced Lung Non-Small Cell Car |
Overview Indication | Colorectal Cancer; Resectable Colorectal Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | binds to G12C mutant KRAS with high affinity and suppresses nucleotide exchange and MAPK signaling |
MoA Biomarker | biomarker-guided treatment algorithms will be essential |
PK/PD Half-life | 5.2 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Sotorasib induces intestinal epithelial injury through suppression of the cAMP/PKA/CREB signaling axis.. Sotorasib, a first-in-class KRAS G12C inhibitor, has demonstrated substantial clinical efficacy in KRAS G12C-mutant malignancies but is frequently associated with gastrointestinal adverse events, the mechanisms of which remain poorly understood. In this study, we investigated the molecular basi… |
Clinical ORR | 0% |
Clinical PFS | 0 |
Clinical OS | 0.75 |
Clinical Result source | ClinicalTrials.gov NCT05313009 |
Clinical Data Tier / Score | A · 42 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교